(Q35007039)

5 August 2017

title

Different black box warning labeling for same-class drugs (English)

1 reference

Despina Contopoulos-Ioannidis

5 August 2017

5

John P A Ioannidis

0 references

2

object named as

Despina G Contopoulos-Ioannidis

1 reference

5 August 2017

Orestis A. Panagiotou

object named as

Orestis A Panagiotou

1

0 references

Evangelia Ntzani

4

object named as

Evangelia E Ntzani

1 reference

5 August 2017

author name string

Panagiotis N Papanikolaou

3

1 reference

5 August 2017

publication date

1 February 2011

1 reference

Journal of General Internal Medicine

5 August 2017

published in

1 reference

5 August 2017

volume

26

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

603-610

1 reference

The formulary process from a risk management perspective

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Formulary decisions: then and now.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Impact of FDA black box advisory on antipsychotic medication use

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Prescriber compliance with black box warnings in older adult patients.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Lost in transmission--FDA drug information that never reaches clinicians

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

The need for improved access to FDA reviews

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Incidence of fatal adverse drug reactions: a population based study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Better reporting of harms in randomized trials: an extension of the CONSORT statement

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Timing of new black box warnings and withdrawals for prescription medications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Evidence based medicine: what it is and what it isn't

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Adherence to black box warnings for prescription medications in outpatients.

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

FDA use of the black box warning: time for reevaluation as a safety tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

Pro: The Food and Drug Administration Black box warning on droperidol is not justified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

After the black box warning: dramatic changes in ED use of droperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

Pediatric prescribing practices and the FDA Black-box warning on antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

The US and European regulatory systems: a comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1633-9

Black box warnings in prescription drug labeling: results of a survey of 206 drugs.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3101972

Boxed warnings and other FDA communication tools

26 October 2018

1 reference

12 December 2020

Coverage of FDA medication boxed warnings in commonly used drug information resources

1 reference

12 December 2020

Adverse events: the more you search, the more you find

1 reference

12 December 2020

FDA drug prescribing warnings: is the black box half empty or half full?

1 reference

12 December 2020

Black box warnings-implications in practice

1 reference

12 December 2020

The New Sentinel Network — Improving the Evidence of Medical-Product Safety

1 reference

12 December 2020

10.1007/S11606-011-1633-9

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference